AlphAIAlphAI — Financial news for AI agents
investing.comOCT 71 min read$OABI

Stifel reiterates OmniAb stock rating on technology platform

Stifel maintained a Buy rating and $9.00 price target for OmniAb (OABI), citing its technology platform and upcoming catalysts. The stock has fallen 12.3% in a week but risen 188% in six months. OmniAb reported Q2 2026 earnings beating estimates, with revenue of $13.41M vs. $4.95M expected.

Original reporting
investing.com
Published Oct 7, 2026, 12:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$OABI
Bullish
medium confidence
Mentioned
$OABI
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OABIBullishLow
01

Why it matters

Analyst upgrade with a higher target may attract buying interest.

02

Market read

Analyst reiteration with a higher price target provides modest new insight but no material corporate event.

03

Timing

none

Relevance 4/10Novelty 2/10Timing: none

Background

OmniAb is a biotech focused on peptide discovery platforms. The article repeats Q2 2026 results that were released over two months earlier.

Company-level read

Ticker impact

$OABIBullishMedium confidence
Context

Stifel reiterated a Buy rating and raised the price target to $9.00 after OmniAb's investor event, providing fresh analyst coverage.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

The new $9 target is more than double the current price, suggesting upside potential despite recent pullback.

Read at source← All news

Related articles

AUG 17
$OABIMedAI 8/10

OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook

OmniAb Inc. (OABI) shares rose about 18% in premarket after the company increased its 2026 cash forecast. OmniAb now expects $49 million to $53 million in cash and cash equivalents, up from $37 million to $41 million, citing recent license and business-development agreements, including a technology contract with Eli Lilly for its ion-channel program.

yahoo.com3 min
AUG 17
$FDMTMed

Top Biotech Gainers: FDMT, OABI, ACXP Rally On Pipeline And Regulatory News

Biotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.

rttnews.com7 min
AUG 17
$OABIMed

OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook

OmniAb Inc. (NASDAQ: OABI) shares rose about 21.6% after the company reported a Q2 earnings beat and raised 2026 revenue guidance to $32M–$36M from $28M–$33M. The article cites Q2 revenue around $13.4M, gross margin near 99.9%, and positive operating and free cash flow. It also notes a Veraxa Biotech collaboration on VXA-222.

stockstotrade.com6 min
AUG 17
$OABIHighAI 9/10

Why is OmniAb stock surging today?

Investing.com reports OmniAb’s shares rose 22.5% in pre-open trading to $4.14, above its prior 52-week high of $3.635. The company announced a global collaboration and license with Eli Lilly for an ion channel drug discovery program, with an upfront payment and up to $370M in milestones plus tiered royalties. OmniAb also raised 2026 cash guidance to $49M-$53M from $37M-$41M.

investing.com4 min